J.W. Cole Advisors Inc. Has $326,000 Holdings in Zoetis Inc. (NYSE:ZTS)

J.W. Cole Advisors Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,650 shares of the company’s stock after purchasing an additional 127 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Zoetis were worth $326,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Zoetis by 7.4% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares during the period. Peak Financial Advisors LLC acquired a new position in shares of Zoetis during the fourth quarter worth approximately $2,776,000. BLB&B Advisors LLC raised its position in shares of Zoetis by 1.9% during the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after purchasing an additional 1,107 shares during the period. Ninety One UK Ltd raised its position in shares of Zoetis by 13.1% during the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after purchasing an additional 12,537 shares during the period. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Zoetis by 10.9% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after purchasing an additional 17,976 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.9 %

Shares of NYSE:ZTS opened at $150.89 on Thursday. The company has a market capitalization of $69.01 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The business has a fifty day moving average price of $173.11 and a two-hundred day moving average price of $179.58. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.15 EPS. Analysts forecast that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group upped their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Stifel Nicolaus decreased their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Finally, Barclays decreased their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus price target of $218.00.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.